Glycogen storage disease type II diagnostic study of choice

Glycogen storage disease type II Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Glycogen storage disease type II from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Glycogen storage disease type II diagnostic study of choice On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Glycogen storage disease type II diagnostic study of choice All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Glycogen storage disease type II diagnostic study of choice
CDC on Glycogen storage disease type II diagnostic study of choice
Glycogen storage disease type II diagnostic study of choice in the news
Blogs on Glycogen storage disease type II diagnostic study of choice
Directions to Hospitals Treating Glycogen storage disease type II
Risk calculators and risk factors for Glycogen storage disease type II diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

• The page name should be "[Disease name] diagnostic study of choice", with only the first letter of the title capitalized. Note that the page is called "Diagnostic study of choice."
• Goal:
  • To describe the most efficient/sensitive/specific test that is utilized for diagnosis of [disease name].
  • To describe the gold standard test for the diagnosis of [disease name].
  • To describe the diagnostic criteria, which may be based on clinical findings, physical exam signs, pathological findings, lab findings, findings on imaging, or even findings that exclude other diseases.
• As with all microchapter pages linking to the main page, at the top of the edit box put {{CMG}}, your name template, and the microchapter navigation template you created at the beginning.
• Remember to create links within WikiDoc by placing [[square brackets]] around key words which you want to link to other pages. Make sure you makes your links as specific as possible. For example, if a sentence contained the phrase anterior spinal artery syndrome, the link should be to anterior spinal artery syndrome not anterior or artery or syndrome. For more information on how to create links, click here.
• Remember to follow the same format and capitalization of letters as outlined in the template below.
• You should include the name of the disease in the first sentence of every subsection.

Diagnostic Study of Choice

Gold standard

• Acid α-glucosidase (GAA) activity in fibroblast of a dried blood sample is the gold standard test for the diagnosis of glycogen storage disease type 2.
• The following result of acid α-glucosidase (GAA) activity in fibroblast of a dried blood sample is confirmatory of glycogen storage disease type 2:
  • Decreased activity of GAA in fibroblasts

Diagnostic algorithms

Algorithms for diagnostic approach of glycogen storage disease type 2

Diagnostic algorithm for Infantile onset glyogen storage disease type II
COMMON PRESENTING SYMPTOMS	CARDIOVASCULAR Cardiomegaly; Congestive heart failure; Arrhythmias such as supraventricular tachycardia; Cardiac arrest during surgery.   PULMONARY Frequent infections; Respiratory distress/ insufficiency.   NEUROLOGICAL Hypotonia; Developmental delay; Gross motor delay; Loss of early motor milestones.   GASTROINTESTINAL Failure to thrive; Feeding difficulties.
PERTINENT PATIENT FINDNGS	CARDIOVASCULAR Murmur, gallop, pulsatile precordium, excessive sweating (cardiac related); Cardiomegaly; Cardiomyopathy; (hypertrophic +/- LVOTO) progressing to dilated cardiomyopathy.   PULMONARY Progressive respiratory involvement, nasal flaring; Use of accessory muscles, IC and SC retractions, decreased breath sounds in LLL; Coarse breath sounds.   NEUROLOGICAL Delayed motor milestones Hypotonia, head lag, floppy baby with ability to "slip through", frog leg position, hypertrophy of gastrocnemius muscle.   GASTROINTESTINAL Macroglossia, open mouth, low facial tone, decreased gag refles, failure to thrive, poor suck and swallow, difficulty feeding with pooling of oral secretions; hepatomegaly.
INITIAL CLINICAL FINDINGS AND INVESTIGATIONS	If GAA present, follow- up with confirmatory testing, if strong clinical suspicion.       CLINICAL STUDIES Chest X-ray- Cardiomegaly; EKG - huge R wave, short PR interval and broad QRS complex; Echocardiography - cardiomyopathy Electrophysiology (EMG/NCS) - myopathy.   LABORATORY (BLOOD OR URINE) Elevated CK, AST, ALT, LDH (in blood) Glc4 (in urine); GAA activity in dried blood spots. lymphocytes, or leukocytes with blocking antibodies to neutral mmaltase; Mutation testing in familial mutation known                                   If GAA absent, obtain confirmatory studies for definitive diagnosis.
CONFIRMATOY STUDIES	DNA GAA mutation testing   ENZYMOLOGY GAA activity testing in fibroblasts or muscle (the gold standard). Caution with muscle biopsy is needed sue to anesthesia risk.   HISTOLOGY/ HISTOCHEMISTRY Increased lysosomal glycogen Vacuolated cells
Adopted from GENETICS IN MEDICINE

Diagnostic algorithm for Late onset (>1 year) glyogen storage disease type II
COMMON PRESENTING SYMPTOMS	PULMONARY Frequent infections; Respiratory insufficiency/distress; Sleep apnea; Somnolence Morning headaches.   MUSCULOSKELETAL Limb girdle weakness Back pain; Exercise tolerance; Rigid spine syndrome.   GASTROINTESTINAL Feeding and swallowing difficulties; Poor weight gain.
PERTINENT PATIENT FINDNGS	RESPIRATORY Respiratory insuffucuency; orthopnea, sleep apnea; exertional dyspnea; Weak cough.   MUSCULOSKELETAL Progressive proximal limb-girdle muscle weakness (lower extremities . upper extremities; gain abnormalities; exercise intolerance; lordosis/scoliosis; hypotonia; lower back pain; Gower sign.   GASTROINTESTINAL Difficulty maintaining normal weight; Difficulty chewing or jaw muscle fatigue; Decreased gag reflex; hepatomegaly.   CARDIOVASCULAR Infrequent cardiomegaly (juveniles).
INITIAL CLINICAL FINDINGS AND INVESTIGATIONS	If GAA present, follow- up with confirmatory testing, if strong clinical suspicion.       CLINICAL STUDIES Lung function testing lying and sitting; Muscle strength testing; Electrophysiology (EMG/NCS) - myopathy; Muscle biopsy - histology and histochemistry.   LABORATORY (BLOOD OR URINE) Elevated CK, AST, ALT, LDH (in blood) Glc4 (in urine); GAA activity in dried blood spots, lymphocytes, or leukocytes with blocking antibodies to neutral mmaltase; Mutation testing in familial mutation known                                   If GAA absent, obtain confirmatory studies for definitive diagnosis.
CONFIRMATOY STUDIES	DNA GAA mutation testing   ENZYMOLOGY GAA activity testing in fibroblasts or muscle (the gold standard); ClinicaL Coorelation with test result is required.   HISTOLOGY/ HISTOCHEMISTRY (dependent on the site of biopsy) Increased lysosomal glycogen Vacuolated cells
Adopted from GENETICS IN MEDICINE